Our nasal spray reduced COVID-19 growth in ferrets by up to 96%: Aus firm
28 Sept 2020
Australian biotech company Ena Respiratory has said a nasal spray that it is developing to improve human immune system to fight common cold and flu significantly reduced coronavirus growth in a recent study on animals. INNA-051 reduced COVID-19 viral replication by up to 96% in ferrets, the company said. The study was led by British government agency Public Health England.
A study on ferrets showed thc product dubbcd INNA-051, which could be used complementary to vaccines, lowered the levels of the virus that causes COVID-19 by up to 96%, the company said. The study was led by British government agency Public Health England. Ena Respiratory said it would be ready to test INNA-051 in human trials in less than four months, subject to successful toxicity studies and regulatory approval.
The company has raised A$11.7 million ($8.24 million) for the development of the spray. Investors include venture capital firm Brandon Capital Ltd, the Australian federal government, pension funds and biotcch giant CSL Ltd.